All In Biotech

Drug Trial Radar · NCT03618355

Trial of eRapa in Prostate Cancer Patients

Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients Under Active Surveillance

Last checked: Nov 19, 2026Latest source record: Mar 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Aug 28, 2018

Primary completion

Dec 2, 2019

Study completion Dec 2, 2019

Sponsor

Sponsor type
Industry
Collaborators
Cancer Insight, LLC
First posted
Aug 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to determine the safety, pharmacokinetics/pharmacodynamics, and immunologic impact of encapsulated rapamycin in patients with low risk prostate cancer under active surveillance. There will be four groups of patients, each receiving a different dose of rapamycin.

Conditions

  • Prostate Cancer

Interventions

  • eRapa (encapsulated rapamycin)Drug

    The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100). This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: After 4 weeks of treatment in each dosing cohort.
  2. Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: After completion of treatment, approximately 12 weeks, in each dosing cohort.
  3. Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur at 1 year.
  4. Primary Safety and Tolerability (Incidence of Treatment-Emergent Adverse Events)Time frame: This will be completed after all dosing cohorts have been enrolled and treated, anticipated to occur after 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT Health San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.